Carveol
Based on 1 publication(s) in Google Scholar
Carveol is an orally active monoterpenoid alcohol with neuroprotective, antioxidant, anti-inflammatory, anticonvulsant, antidiabetic, hypolipidemic and hepatoprotective activities. Carveol upregulates the expression of Bcl2, downregulates the expression of caspase-3, TNF-α, IL1β and IL6, activates the Nrf2/HO-1 antioxidant signaling pathway, inhibits the RAGE/NF-κB signaling pathway, and suppresses neuroinflammation and neuronal apoptosis. Carveol inhibits α-synuclein aggregation, improves cognitive ability, and inhibits α-amylase activity. Carveol exerts neuroprotective effects in a rat model of Parkinson's disease. Carveol exhibits antidiabetic effects in alloxan-induced diabetic rats. Carveol alleviates PTZ-induced seizures in rats. Carveol can be used in research related to Parkinson's disease, epilepsy, diabetes and ischemic stroke.
For research use only. We do not sell to patients.
- Purity : 98.32%
- CAS No.: 99-48-9
- Formula: C10H16O
- Molecular Weight:152.24
-
Storage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Carveol
MoreAll Caspase Isoforms
MoreAll α-synuclein Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
IL-6 |
IL-1β |
Caspase 3 |
TNF-α |
In Vitro
Carveol binds to multiple human diabetes-related target proteins with differential binding affinities, among which it shows the highest binding affinity for sodium-glucose cotransporters (ACE value = -7.3 Kcal/mol)[3].
Carveol (0.821-65.690 μM; 30 min) inhibits the activity of purified α-amylase in a concentration-dependent manner, with an inhibition rate of 73.01% at the concentration of 65.690 μM[3].
Carveol binds to the Nrf2-binding site of purified Keap1 protein[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Carveol (20 mg/kg; i.p.; once daily; for 35 consecutive days) is well tolerated in healthy rats, with no adverse effects on motor function, neurochemical balance, oxidative status, inflammation or neuronal structure, while significantly upregulating the expression of BDNF mRNA[1].
Carveol (10-20 mg/kg, i.p., administered 30 minutes prior to each pentylenetetrazol (PTZ) injection, once every 48 hours for 15 consecutive days) attenuates PTZ-induced seizures, cognitive impairment, oxidative stress, neuroinflammation and blood-brain barrier disruption in male Sprague-Dawley rats by activating the Nrf2/HO-1 signaling pathway[2].
Carveol (65.7-394.1 µM/Kg; administered for 12 days; observed for 6 weeks) exhibits dose-dependent antidiabetic, antihyperlipidemic, and hepatoprotective effects in alloxan-induced diabetic Sprague-Dawley rats, including significant reductions in blood glucose, HbA1C, triglycerides (TGs), low-density lipoprotein (LDL), and hepatic enzyme levels, along with an increase in high-density lipoprotein (HDL)[3].
Carveol (10-20 mg/kg, intraperitoneally administered at 30 min and 24-72 h after MCAO) exerts a dose-dependent neuroprotective effect against MCAO-induced ischemic stroke; at the dose of 20 mg/kg, it reduces the corrected infarct size to 19.2%, restores the levels of key antioxidant enzymes, and inhibits neuroinflammation and apoptosis by activating the Nrf2 pathway[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rats (rotenone-induced Parkinson’s disease)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; daily; 35 days
-
Result:Significantly reduced time spent in the open-field periphery, increased time spent in the center, and decreased grooming and rearing occurrences compared to rotenone-only rats.
Significantly increased striatal dopamine, serotonin, and GABA levels, and upregulated tyrosine hydroxylase immunoreactivity and brain-derived neurotrophic factor (BDNF) mRNA expression compared to rotenone-only rats; 20 mg/kg dose showed greater increases in these markers.
Significantly downregulated striatal α-synuclein protein expression compared to rotenone-only rats.
Significantly reduced striatal malondialdehyde and nitric oxide levels, and increased glutathione, superoxide dismutase, catalase, and glutathione peroxidase levels compared to rotenone-only rats.
Significantly upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) mRNA expression compared to rotenone-only rats, with the 20 mg/kg dose showing higher expression levels.
Significantly reduced striatal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 levels, and downregulated receptor for advanced glycation endproducts (RAGE) and nuclear factor kappa-B (NF-κB) mRNA and NF-κB protein expression compared to rotenone-only rats.
Significantly reduced glial fibrillary acidic protein (GFAP) immunoreactivity in the striatum and substantia nigra compared to rotenone-only rats, with the 20 mg/kg dose showing greater reduction.
Significantly increased Bcl-2 mRNA expression and reduced caspase-3 mRNA expression and immunoreactivity in the striatum and substantia nigra compared to rotenone-only rats.
Reduced the number of degenerated, shrunken neurons and pyknotic glial nuclei in hematoxylin and eosin-stained striatal and substantia nigra tissues, with the 20 mg/kg dose showing more preserved tissue architecture.
Reduced the number of darkly stained, shrunken neurons in Cresyl violet-stained striatal and substantia nigra tissues.
-
Animal Model:Sprague-Dawley (adult male, weight 250-300 g, PTZ-induced epilepsy kindling model)[2]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; 30 min before each PTZ injection; every 48 h; 15 days
-
Result:Reduced mean seizure intensity score, decreased seizure frequency, extended seizure latency, and improved survival to 85% at 10 mg/kg compared to PTZ-only rats.
Reduced mean seizure intensity score, decreased seizure frequency, extended seizure latency, and improved survival to 100% at 20 mg/kg compared to PTZ-only rats (71.4% survival).
Reduced escape latency in the Morris Water Maze hidden-platform test at both 10 mg/kg and 20 mg/kg compared to PTZ-only rats.
Increased time spent in the target quadrant at 10 mg/kg, and at 20 mg/kg compared to PTZ-only rats.
Significantly increased the number of intact neurons in the cortex, hippocampal CA1, CA3, and DG regions at 20 mg/kg, reversing PTZ-induced neuronal atrophy, pyknosis, and karyolysis.
Restored cortical and hippocampal levels of catalase, superoxide dismutase, glutathione-S-transferase, and reduced glutathione at both doses compared to PTZ-only rats.
Reduced thiobarbituric acid reactive substance in both brain regions at 20 mg/kg compared to PTZ-only rats.
Significantly upregulated cortical and hippocampal Nrf2 gene expression and protein localization, as well as downstream heme oxygenase-1 (HO-1) gene and protein expression at 20 mg/kg compared to PTZ-only rats.
Reduced cortical and hippocampal levels of tumor necrosis factor-alpha, phosphorylated nuclear factor kappa B, cyclooxygenase-2, and acetylcholinesterase at 20 mg/kg compared to PTZ-only rats.
Reduced cortical and hippocampal DG vascular endothelial growth factor (VEGF) expression at 20 mg/kg, reversing PTZ-induced BBB disruption.
Abolished all carveol-mediated protective effects when pretreated with the Nrf2 inhibitor ATRA.
-
Animal Model:Sprague-Dawley (SD) (adult, either sex, 7-11 weeks old, 250-280 g, alloxan-induced diabetic)[3]
-
Dosage:65.7 µM/Kg; 197 µM/Kg; 394.1 µM/Kg
-
Administration:12 days; 6 weeks (for biomarker analysis)
-
Result:Attenuated alloxan-induced hyperglycemia in a dose- and time-dependent manner across days 1, 3, 6, 9, and 12, with statistically significant reductions compared to the diabetic control group.
Improved oral glucose tolerance at 394.1 µM/Kg, with statistically significant reductions in blood glucose levels at 30, 60, 90, and 120 minutes after glucose load compared to the diabetic control group.
Reduced glycosylated hemoglobin (HbA1C) levels in a dose-dependent manner: 65.7 µM/Kg reduced HbA1C to 5.6%, 197 µM/Kg reduced it to 5.2%, and 394.1 µM/Kg reduced it to 4.9%.
Reduced triglycerides (TGs), LDL, and increased HDL in a dose-dependent manner: 65.7 µM/Kg reduced TGs to 131.3 mg/dL, LDL to 75.2 mg/dL, and increased HDL to 50.2 mg/dL; 197 µM/Kg reduced TGs to 122.3 mg/dL, LDL to 73.6 mg/dL, and increased HDL to 50.6 mg/dL; 394.1 µM/Kg reduced TGs to 120.4 mg/dL, LDL to 65 mg/dL, and increased HDL to 51 mg/dL.
Reduced hepatic biomarker levels in a dose-dependent manner: 65.7 µM/Kg reduced ALT to 38 u/L, AST to 27.7 u/L, ALP to 200.2 u/L, and total bilirubin (TB) to 0.67 mg/dL; 197 µM/Kg reduced ALT to 28.6 u/L, AST to 25 u/L, ALP to 185.3 u/L, and TB to 0.76 mg/dL; 394.1 µM/Kg reduced ALT to 25.6 u/L, AST to 23.8 u/L, ALP to 186.8 u/L, and TB to 0.7 mg/dL.
Reduced body weight across days 1, 3, 6, 9, and 12, with statistically significant differences compared to the diabetic control group.
-
Animal Model:Sprague-Dawley (male, 7-10 weeks old, 230-260 g, transient middle cerebral artery occlusion for 120 minutes followed by 72 hours of reperfusion)[4]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; administered at 30 min, 24, 48, and 72 h post-MCAO
-
Result:Significantly reversed MCAO-induced neurological deficits at 72 hours, with 10 mg/kg and 20 mg/kg showing dose-dependent efficacy.
Reduced MCAO-induced corrected infarct area from 33.14% to 26.5% and 19.2%.
Significantly increased the number of surviving neurons in the cortex and striatum and attenuated MCAO-induced neuronal morphological damage.
Restored cortical GSH levels to 41.4 μmoles/mg protein, GST activity to 27.9 μmoles CDNB conjugate/min/mg protein, and catalase activity to 17.1 μmoles H2O2/min/mg protein.
Reduced cortical LPO content to 63.8 TBARS-nM/min/mg protein.
Significantly reduced cortical TNF-α levels, p-JNK expression in the cortex and striatum, and p-NFκB expression.
Increased cortical Nrf2 protein expression and HO-1 protein expression.
Significantly reduced MCAO-induced brain water content.
Attenuated MCAO-induced caspase-3 expression and increased Bcl2 expression in the cortex and striatum.
Chemical Information
-
CAS No. 99-48-9
-
Appearance Liquid (Density: 0.958 g/cm3)
-
Molecular Weight 152.24
-
Formula C10H16O
-
Color Colorless to light yellow
-
SMILES
OC1C(C)=CCC(C(C)=C)C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Chem Biol Interact
Carveol alleviates osteoarthritis progression by acting on synovial macrophage polarization transformation: An in vitro and in vivo study. [Abstract]2024 Jan 5:387:110781. PMID: 37967808
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (656.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
-
Data Sheet (295 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[2]. Alvi AM, et al. Carveol Attenuates Seizure Severity and Neuroinflammation in Pentylenetetrazole-Kindled Epileptic Rats by Regulating the Signaling Pathway. Oxidative medicine and cellular longevity. 2021;2021:9966663. [Content Brief]
[3]. Ahmed MS, et al. Computational and Pharmacological Evaluation of Carveol for Antidiabetic Potential. Frontiers in pharmacology. 2020;11:919. [Content Brief]
[4]. Malik I, et al. Potent Natural Antioxidant Carveol Attenuates MCAO-Stress Induced Oxidative, Neurodegeneration by Regulating the Nrf-2 Pathway. Frontiers in neuroscience. 2020;14:659. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.5686 mL | 32.8429 mL | 65.6858 mL | 164.2144 mL |
| 5 mM | 1.3137 mL | 6.5686 mL | 13.1372 mL | 32.8429 mL | |
| 10 mM | 0.6569 mL | 3.2843 mL | 6.5686 mL | 16.4214 mL | |
| 15 mM | 0.4379 mL | 2.1895 mL | 4.3791 mL | 10.9476 mL | |
| 20 mM | 0.3284 mL | 1.6421 mL | 3.2843 mL | 8.2107 mL | |
| 25 mM | 0.2627 mL | 1.3137 mL | 2.6274 mL | 6.5686 mL | |
| 30 mM | 0.2190 mL | 1.0948 mL | 2.1895 mL | 5.4738 mL | |
| 40 mM | 0.1642 mL | 0.8211 mL | 1.6421 mL | 4.1054 mL | |
| 50 mM | 0.1314 mL | 0.6569 mL | 1.3137 mL | 3.2843 mL | |
| 60 mM | 0.1095 mL | 0.5474 mL | 1.0948 mL | 2.7369 mL | |
| 80 mM | 0.0821 mL | 0.4105 mL | 0.8211 mL | 2.0527 mL | |
| 100 mM | 0.0657 mL | 0.3284 mL | 0.6569 mL | 1.6421 mL |
Keywords
- Carveol
- 99-48-9
- Bcl-2 Family
- Caspase
- TNF Receptor
- Interleukin Related
- Keap1-Nrf2
- Heme Oxygenase (HO)
- NF-κB
- Apoptosis
- α-synuclein
- Amylases
- epilepsy
- Nrf2/HO-1 antioxidant signaling
- Parkinson’s disease
- blood-brain barrier
- diabetes mellitus
- RAGE/NF-κB signaling
- Keap1
- alpha-amylase
- Bcl2/caspase-3 apoptotic signaling
- Inhibitor
- inhibitor
- inhibit